Get the Stockscreener App
6.64
0.34%
-0.00
Recursion Pharmaceuticals Inc stock is traded at $6.64, with a volume of 1.89M.
It is down -0.34% in the last 24 hours and up +8.30% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$6.64
Open:
$6.59
24h Volume:
1.89M
Relative Volume:
0.40
Market Cap:
$1.91B
Revenue:
$43.88M
Net Income/Loss:
$-328.07M
P/E Ratio:
-4.8116
EPS:
-1.38
Net Cash Flow:
$-300.33M
1W Performance:
-1.82%
1M Performance:
+8.30%
6M Performance:
-25.14%
1Y Performance:
+11.97%
1-Day Range:
$6.465
$6.64
1-Week Range:
$6.22
$6.90
52-Week Range:
$5.035
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Vanguard Group Inc's Strategic Acquisition in Recursion Pharmace - GuruFocus.com
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - MSN
(RXRX) Technical Pivots with Risk Controls - Stock Traders Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker? - AOL
Mirae Asset Global Investments Co. Ltd. Purchases 80,664 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Is Recursion Pharmaceuticals a Millionaire-Maker Stock? - MSN
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com
Recursion Pharmaceuticals director Blake Borgeson sells $76,926 in stock - Investing.com India
Recursion Pharmaceuticals director Blake Borgeson sells $76,926 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals (RXRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th - StockTitan
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.6% After Insider Selling - MarketBeat
Recursion Pharmaceuticals president Tina Marriott sells $37,854 in stock By Investing.com - Investing.com Canada
Recursion Pharmaceuticals president Tina Marriott sells $37,854 in stock - Investing.com
Tina Marriott Sells 6,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 5.1%Here's What Happened - MarketBeat
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.8%Here's What Happened - MarketBeat
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.2%Here's What Happened - MarketBeat
(RXRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.9%Here's What Happened - MarketBeat
Recursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech Innovation - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.5%Here's What Happened - MarketBeat
Recursion Pharmaceuticals, Inc. - Via Ritzau
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.6%Should You Sell? - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know - MSN
State Street Corp's Strategic Acquisition in the Biotechnology Sector - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 2.9%Here's What Happened - MarketBeat
Recursion Pharmaceuticals director Blake Borgeson sells $76,326 in stock - Investing.com
Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals director Blake Borgeson sells $76,326 in stock By Investing.com - Investing.com UK
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.3%Here's Why - MarketBeat
Prediction: These 2 Stocks Could Soar in 2025 - sharewise
What's Going On With Recursion Pharmaceuticals Stock? - MSN
Machine learning in drug discovery speeds up development - SiliconANGLE News
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.9% HigherStill a Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.4%Should You Sell? - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, ARC, RXRX on Behalf of Shareholders - The Malaysian Reserve
Cathie Wood Is Betting on This AI Stock: Is It a Buy? - Yahoo! Voices
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip? - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.6%Should You Sell? - MarketBeat
Metachromatic Leukodystrophy Treatment Market Size And Forecast -ArmaGen, Inc., GlaxoSmithKline Plc, Recursion Pharmaceu – IndiaPolitics.com - IndiaPolitics.com
(RXRX) Investment Report - Stock Traders Daily
Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery - Yahoo Finance
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI - AccessWire
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1% HigherWhat's Next? - MarketBeat
Exscientia Set for Strategic Acquisition by Recursion - Yahoo Finance
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):